Closed Solicitation · DEPARTMENT OF HEALTH AND HUMAN SERVICES
AI Summary
The Department of Health and Human Services has awarded a contract to Orexo US, Inc. for the clinical development of OX390, an alpha-2 agonist reversal agent. This project aims to counteract the sedative effects of certain drugs increasingly used in combination with IMF. Interested parties should note the details of this award for potential future opportunities.
Award Notice for Orexo US, Inc. (Contract 75A50125C00010). Clinical development of OX390 (atipamezole) as an α2 agonist reversal agent for human use to counteract the sedative effects of xylazine, medetomidine, and other α2 agonists that are increasingly found in combination with IMF.
NOTICE OF CONTRACT AWARD - OREXO US, INC. is a federal acquisition solicitation issued by DEPARTMENT OF HEALTH AND HUMAN SERVICES. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.